This article has been updated to correctly represent the interim survival analysis for patients who cleared ctDNA at any point after treatment.
NEW YORK – Researchers have demonstrated in a Phase II study that customized circulating tumor DNA (ctDNA) assays designed by genetic testing firm Natera could potentially be useful for monitoring whether patients with a variety of cancers will respond to immunotherapy.